Pretreatment CD4 cell slope and progression to AIDS or death in HIV-infected patients initiating antiretroviral therapy--the CASCADE collaboration: a collaboration of 23 cohort studies.
about
Identifying Recent HIV Infections: From Serological Assays to GenomicsEffects of valacyclovir on markers of disease progression in postpartum women co-infected with HIV-1 and herpes simplex virus-2Joint modeling of survival and longitudinal non-survival data: current methods and issues. Report of the DIA Bayesian joint modeling working groupFractional Brownian motion and multivariate-t models for longitudinal biomedical data, with application to CD4 counts in HIV-positive patients.Combined models for pre- and post-treatment longitudinal biomarker data: an application to CD4 counts in HIV-patients.Estimation of the linear mixed integrated Ornstein-Uhlenbeck model.Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients.HIV treatment as prevention: the utility and limitations of ecological observation.Adjusting for measurement error in baseline prognostic biomarkers included in a time-to-event analysis: a joint modelling approach.Symptomatic illness and low CD4 cell count at HIV seroconversion as markers of severe primary HIV infection.Effect of selenium supplementation on CD4 T-cell recovery, viral suppression, morbidity and quality of life of HIV-infected patients in Rwanda: study protocol for a randomized controlled trial.Type 1 interferons suppress accelerated osteoclastogenesis and prevent loss of bone mass during systemic inflammatory responses to Pneumocystis lung infection.Estimation of the Undiagnosed Intervals of HIV-Infected Individuals by a Modified Back-Calculation Method for Reconstructing the Epidemic CurvesEconomic and epidemiological impact of early antiretroviral therapy initiation in India.The Epidemiologic and Economic Impact of Improving HIV Testing, Linkage, and Retention in Care in the United StatesUpdates to the Spectrum/Estimation and Projection Package (EPP) model to estimate HIV trends for adults and children.Factors affecting timing of antiretroviral treatment initiation based on monitoring CD4 counts.Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study.Early diagnosis and treatment of HIV infection: magnitude of benefit on short-term mortality is greatest in older adultsIncreases in duration of first highly active antiretroviral therapy over time (1996-2009) and associated factors in the Multicenter AIDS Cohort Study.CD4 cell eligibility thresholds: an analysis of the time to antiretroviral treatment in HIV-1 seroconverters.Diversity of Pneumocystis jirovecii Across Europe: A Multicentre Observational StudyImmune Suppression by Myeloid Cells in HIV Infection: New Targets for ImmunotherapyRate of decline in CD4 count in HIV patients not on antiretroviral therapy.Influence of model assumptions about HIV disease progression after initiating or stopping treatment on estimates of infections and deaths averted by scaling up antiretroviral therapy.
P2860
Q26778001-59A804E2-51EE-4AF6-98CB-CBE2E2928808Q28728582-F1982B3C-8F09-4BD2-93AA-578A04FF7007Q30779044-91EA341B-0CAB-4F4D-89EC-6DB2ED59B57BQ31021008-ECED0D77-4CFC-478F-9FA1-DA11673731F1Q31131058-EC017A72-76A0-43AA-A511-F82B5F97B1B9Q33609820-25F9C20B-90FD-4F48-BE9A-10CD21461765Q33987654-D850A25A-4450-4827-9717-388138C1ABA5Q34339533-9868FD26-69D6-4828-A34F-3440607ACC67Q34448564-6C5307F5-1EFB-4F13-B322-8A9056BCE865Q35045387-268986F7-A5BB-4DC9-9CEF-87DC76B66ADBQ35240769-181E7E68-DED3-4A54-8822-CC8A0F8357BBQ36071793-E5C0179D-02A1-4C69-802B-54B6B02EED44Q36073757-4450E8A3-B2B0-4957-951F-76623B0E61BDQ36119499-1E231543-EFED-4AA2-8ECC-53533A804AC4Q36402466-5C8426EB-80FC-44A4-B380-106116D293FAQ36440560-14BCC2FE-2006-4379-82E6-4A9B6E088CCCQ36831346-3F39FA10-0549-46E5-8EB9-AF8EA7A4A057Q36875697-4B4D0A85-20B0-4FE3-BC8E-C7893A44F262Q36933509-7035D94E-0BB1-41B9-8C39-1508B4BFC311Q37497586-409AE643-EC8B-4670-A0E6-0968060B0117Q37578944-2A9DB15E-0E82-4DDB-B846-B5B8E73D527DQ38680375-F9D77DE5-F56B-4DE7-AD5E-41E90D46ADDAQ39048479-04A66AEF-C742-4754-B733-C5B6BA4DB5A5Q39480210-22836540-5777-438D-9EF3-FBF04C82B850Q52648768-B8FE7EDC-5260-46B3-BB0C-9F42AC42AFEC
P2860
Pretreatment CD4 cell slope and progression to AIDS or death in HIV-infected patients initiating antiretroviral therapy--the CASCADE collaboration: a collaboration of 23 cohort studies.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Pretreatment CD4 cell slope an ...... boration of 23 cohort studies.
@ast
Pretreatment CD4 cell slope an ...... boration of 23 cohort studies.
@en
Pretreatment CD4 cell slope an ...... boration of 23 cohort studies.
@nl
type
label
Pretreatment CD4 cell slope an ...... boration of 23 cohort studies.
@ast
Pretreatment CD4 cell slope an ...... boration of 23 cohort studies.
@en
Pretreatment CD4 cell slope an ...... boration of 23 cohort studies.
@nl
prefLabel
Pretreatment CD4 cell slope an ...... boration of 23 cohort studies.
@ast
Pretreatment CD4 cell slope an ...... boration of 23 cohort studies.
@en
Pretreatment CD4 cell slope an ...... boration of 23 cohort studies.
@nl
P2093
P2860
P50
P921
P1433
P1476
Pretreatment CD4 cell slope an ...... boration of 23 cohort studies.
@en
P2093
Abdel Babiker
CASCADE Collaboration Members
Cristina Mussini
Heiner C Bucher
Marcel Wolbers
P2860
P304
P356
10.1371/JOURNAL.PMED.1000239
P407
P577
2010-02-23T00:00:00Z